Short Interest in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Declines By 97.1%

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 500 shares, a decrease of 97.1% from the February 28th total of 17,500 shares. Based on an average daily trading volume, of 365,200 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Provectus Biopharmaceuticals Trading Up 9.1 %

Shares of OTCMKTS:PVCT traded up $0.01 during midday trading on Friday, hitting $0.10. 160,001 shares of the stock were exchanged, compared to its average volume of 236,517. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.20. The company has a 50 day moving average price of $0.11 and a 200-day moving average price of $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.